Company Name: | Vanda Pharmaceuticals Inc | | Ticker Symbol: | VNDA | CIK Number: | 0001347178 | WWW Address: | http://www.vandapharma.com |
CEO: | Dr. Mihael Hristos Polymeropoulos,M.D. | No. of Employees: | 142 |
Common Issue Type: | CS | Business Description: | Vanda Pharmaceuticals Inc. is a biopharmaceutical Company focusing on the development and commercialization of clinical-stage drug candidates for central nervous system disorders.
|
| | Industry Information: | DRUGS - Biotechnology [more like this] |
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | 21.11 | 0.0 | 20.58 | 20.8 | | 21.14 | 19.70 | 3571 |
Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
1,107.2 | 52.4 | 0.00 | -0.35 | 0.00 | 0.0 | 0.0 | 33.44 - 13.88 |
| KEY FIGURES (Latest Twelve Months - LTM) | Yesterday's Close | 21.11 | $ | PE Ratio - LTM | 0.0 | |
Market Capitalisation | 1,107.2 | mil |
Latest Shares Outstanding | 52.4 | mil |
Earnings pS (EPS) | -0.35 | $ |
Dividend pS (DPS) | 0.00 | ¢ |
Dividend Yield | 0.0 | % |
Dividend Payout Ratio | | % |
Revenue per Employee | 604,700 | $ |
Effective Tax Rate | 0.0 | % |
Float | 50.9 | mil |
Float as % of Shares Outstanding | 1.0 | % |
Foreign Sales | | mil |
Domestic Sales | | mil |
Selling, General & Adm/tive (SG&A) as % of Revenue | 0.80 | % |
Research & Devlopment (R&D) as % of Revenue | 0.20 | % |
Gross Profit Margin | 0.0 | % |
EBITDA Margin | 0.0 | % |
Pre-Tax Profit Margin | 0.0 | % |
Assets Turnover | 0.0 | % |
Return on Assets (ROA) | 0.0 | % |
Return on Equity (ROE) | 0.0 | % |
Return on Capital Invested (ROCI) | 0.0 | % |
Current Ratio | | |
Leverage Ratio (Assets/Equity) | | |
Interest Cover | | |
Total Debt/Equity (Gearing Ratio) | | |
LT Debt/Total Capital | 0.0 | % |
Working Capital pS | 1.90 | $ |
Cash pS | 0.00 | $ |
Book-Value pS | 4.98 | $ |
Tangible Book-Value pS | 2.01 | $ |
Cash Flow pS | 0.36 | $ |
Free Cash Flow pS | -0.15 | $ |
 |
KEY FIGURES (LTM): Price info |
Price/Book Ratio | 3.80 | |
Price/Tangible Book Ratio | 0.00 | |
Price/Cash Flow | 52.6 | |
Price/Free Cash Flow | | |
P/E as % of Industry Group | 0.0 | % |
P/E as % of Sector Segment | 0.0 | % |
| | Balance Sheet (at a glance) in Millions |
| | | DIVIDEND INFO | Type of Payment | - |
Dividend Rate | 0.00 |
Current Dividend Yield | 0.0 |
5-Y Average Dividend Yield | 0.0 |
Payout Ratio | 0.0 |
5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | Share price performance previous 3 years |
| 
|  | Share price performance intraday |
| 
| | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
1 Week | - | - | - | 11.8 | | 1,932,686 | |
4 Weeks | 31.00 | 17.05 | 30.03 | -33.0 | | 1,305,891 | 24,811,943 |
13 Weeks | 33.44 | 17.05 | 23.60 | -14.7 | | 893,619 | 53,617,171 |
26 Weeks | 33.44 | 17.05 | 21.10 | -4.6 | | 915,009 | 113,461,192 |
52 Weeks | 33.44 | 13.88 | 17.30 | 16.3 | | 743,692 | 185,923,125 |
YTD | 31.39 | 17.05 | - | -25.5 | | 1,013,958 | 32,446,687 |
Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 19.21 | 20.44 | 25.97 | 23.07 | 21.69 | 0.00 | 0.00 |
| | GROWTH RATES | 5-Year Growh | R² of 5-Year Growth | 3-Year Growth |
Revenue | | 0.0 | |
Income | | 0.0 | |
Dividend | | 0.0 | |
Capital Spending | | NA | |
R&D | 5.32 | NA | 50.96 |
Normalized Inc. | 0.00 | NA | 0.00 |
| | CHANGES | YTD vs. Last YTD | Curr Qtr vs. Qtr 1-Yr ago | Annual vs. Last Annual |
Revenue % | -0.9 | -0.9 | 4.7 |
Earnings % | 0.0 | 0.0 | 0.0 |
EPS % | 0.0 | 0.0 | 0.0 |
EPS $ | 0.13 | 0.13 | -0.63 |
| | SOLVENCY RATIOS | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
Net Working Capital Ratio | 48.43 |
Current Ratio | 2.4 |
Quick Ratio (Acid Test) | 2.3 |
Liquidity Ratio (Cash) | 2.52 |
Receivables Turnover | 8.7 |
Average Collection Period | 41 |
Working Capital/Equity | 75.7 |
Working Capital pS | 2.19 |
Cash-Flow pS | -0.04 |
Free Cash-Flow pS | -0.08 |
FINANCIAL STRUCTURE RATIOS |
Altman's Z-Score Ratio | 9.06 |
Financial Leverage Ratio (Assets/Equity) | 0.0 |
Debt Ratio | 0.0 |
Total Debt/Equity (Gearing Ratio) | 0.00 |
LT Debt/Equity | 0.00 |
LT Debt/Capital Invested | 2.8 |
LT Debt/Total Liabilities | 0.0 |
Interest Cover | 0.0 |
Interest/Capital Invested | 0.00 |
| | VALUATION RATIOS | MULTIPLES |
PQ Ratio | 0.00 |
Tobin's Q Ratio | 4.84 |
Current P/E Ratio - LTM | 0.00 |
Enterprise Value (EV)/EBITDA | -64.01 |
Enterprise Value (EV)/Free Cash Flow | -269.25 |
Dividend Yield | 0.0 |
Price/Tangible Book Ratio - LTM | 0.00 |
Price/Book Ratio - LTM | 3.80 |
Price/Cash Flow Ratio | 52.6 |
Price/Free Cash Flow Ratio - LTM | |
Price/Sales Ratio | 0.00 |
P/E Ratio (1 month ago) - LTM | 0.0 |
P/E Ratio (26 weeks ago) - LTM | 0.0 |
P/E Ratio (52 weeks ago) - LTM | 0.0 |
5-Y High P/E Ratio | 139.3 |
5-Y Low P/E Ratio | 28.8 |
5-Y Average P/E Ratio | 0.0 |
Current P/E Ratio as % of 5-Y Average P/E | -6 |
P/E as % of Industry Group | 0.0 |
P/E as % of Sector Segment | 0.0 |
Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
PER SHARE FIGURES |
LT Debt pS | 0.00 |
Current Liabilities pS | 1.61 |
Tangible Book Value pS - LTM | 2.01 |
Book Value pS - LTM | 4.98 |
Capital Invested pS | 2.51 |
Cash pS - LTM | 0.00 |
Cash Flow pS - LTM | 0.36 |
Free Cash Flow pS - LTM | -0.15 |
Earnings pS (EPS) | -0.35 |
| | OPERATING RATIOS | PROFITABILITY RATIOS |
Free Cash Flow Margin | -2.21 |
Free Cash Flow Margin 5YEAR AVG | -59.43 |
Net Profit Margin | -0.1 |
Net Profit Margin - 5YEAR AVRG. | |
Equity Productivity | 1.26 |
Return on Equity (ROE) | -0.1 |
Return on Equity (ROE) - 5YEAR AVRG. | |
Capital Invested Productivity | 1.26 |
Return on Capital Invested (ROCI) | -0.2 |
Return on Capital Invested (ROCI) - 5YEAR AVRG. | |
Assets Productivity | 0.80 |
Return on Assets (ROA) | -0.1 |
Return on Assets (ROA) - 5YEAR AVRG. | |
Gross Profit Margin | 0.0 |
Gross Profit Margin - 5YEAR AVRG. | |
EBITDA Margin - LTM | 0.0 |
EBIT Margin - LTM | 0.0 |
Pre-Tax Profit Margin | -0.2 |
Pre-Tax Profit Margin - 5YEAR AVRG. | |
Effective Tax Rate | 0.0 |
Effective Tax Rate - 5YEAR AVRG. | 0.0 |
EFFICIENCY RATIOS |
Cash Conversion Cycle | 420,429 |
Revenue per Employee | 604,700 |
Net Income per Employee | |
Average Collection Period | 420,429 |
Receivables Turnover | 8.7 |
Day's Inventory Turnover Ratio | |
Inventory Turnover | 22.0 |
Inventory/Sales | 0.5 |
Accounts Payble/Sales | 0.00 |
Assets/Revenue | 1.25 |
Net Working Capital Turnover | 1.66 |
Fixed Assets Turnover | 4.64 |
Total Assets Turnover | 0.8 |
Revenue per $ Cash | 4.91 |
Revenue per $ Plant | 31.11 |
Revenue per $ Common Equity | 1.26 |
Revenue per $ Capital Invested | 1.26 |
Selling, General & Adm/tive (SG&A) as % of Revenue | 75.0 |
SG&A Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
Research & Devlopment (R&D) as % of Revenue | 23.4 |
R&D Expense as % of Revenue - 5YEAR AVRG. | 23.4 |
|
|  





| |  |  | | |